Navigation Links
Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
Date:1/22/2009

campaign during the Amgen Tour of California to help spread the word about working together to conquer cancer.

Breakaway from Cancer Charity Rides

To raise awareness and funds for people affected by cancer, Breakaway from Cancer charity bicycle rides will take place in San Francisco and Thousand Oaks, Calif. on Sunday, Feb. 8. The San Francisco ride will encompass a moderate 25-mile course, and Thousand Oaks will offer either a 25- or 50-mile course. Both events will feature finish line activities. In addition, participants in the San Francisco ride will have the opportunity to meet professional cyclist and Amgen Tour of California stage winner George Hincapie and Thousand Oaks cyclists will meet Team Columbia riders. Interested riders can register by visiting www.breakawayfromcancer.com.

"Since the inaugural Amgen Tour of California, I have been a part of the Breakaway from Cancer initiative," said Hincapie. "Nearly everyone is touched by cancer, including my family, and it's important for those affected to realize they don't have to face the illness alone. Just as in cycling where it takes a support team to help a rider break away from the pack, it takes a strong support network to help a person with cancer face the many hurdles throughout treatment."

Breakaway Miles During the Amgen Tour of California

In honor of cancer survivors everywhere with the spotlight on one special local survivor, Amgen created the Breakaway Mile -- an honorary one-mile bike ride that takes place at the finish line of the Amgen Tour of California, prior to the stage conclusion of the professional race. The Breakaway Mile will take place in four 2009 race host cities: Santa Rosa, Modesto, Paso Robles and Escondido. Each Breakaway Mile will feature a local cancer survivor and an Amgen scientist wh
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
...  Frank A. Critz, M.D., founder and medical director of Radiotherapy ... welcome this April when he returns to Fulton, Miss.  for ... will be April 14, 2012 at the Holiday Inn Express ... until 3 p.m., and lunch will be served. ...
... 20, 2012 The American College of Radiology (ACR) ... Donald P. Rosen, MD, chief executive officer of ACR ... research organization (CRO) and for-profit subsidiary of the ACR. ... of experience in radiology, including contract research and business ...
... Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm ... Virus (HIV) infections, announced today that it has ... pursuant to which the Company has agreed to ... stock at an aggregate purchase price of approximately ...
Cached Biology Technology:Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2Imaging Contract-Research Pioneer, Donald P. Rosen, MD, Named CEO of ACR Image Metrix™ 2GeoVax Announces Private Placement of $2.2 Million 2GeoVax Announces Private Placement of $2.2 Million 3GeoVax Announces Private Placement of $2.2 Million 4
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
(Date:4/17/2014)... on a novel method to help kidney stone ... effective treatment possible., Kidney stones represent a major ... If left untreated, apart from being particularly painful, ... complications. In many patients treated successfully, stone recurrence ... pathological approach to diagnosis and treatment needs to ...
(Date:4/17/2014)... Gene expression is the process whereby the genetic ... products, such as proteins, which have numerous different ... as an important intermediary during gene expression, by ... molecular mechanisms involved in manufacturing proteins. , ... mRNA molecules present in an organism at a ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Rapid and accurate mRNA detection in plant tissues 2
... protein kinase is an essential regulator of cytoskeletal ... whether Rho kinase regulates microtubule remodeling or the ... remains unclear. By using the ROCK inhibitor, Y-27632, ... colleagues from First Affiliated Hospital of Jinan University ...
... know about MyPyramid the triangle depicting how many servings ... - but who knows about MyPlate - the circle showing ... 2011 by the United States Department of Agriculture (USDA) to ... a simple, colorful icon that prompts us to think about ...
... cell-based gene therapy holds promise for the treatment of devastating ... approach have been unclear. In a study online December 26th ... published by Cell Press, researchers evaluated a patient with a ... years after he had undergone a gene therapy procedure as ...
Cached Biology News:Who is using MyPlate? 2Gene therapy for human skin disease produces long-term benefits 2